Enable Biosciences Receives $1.5 M Grant from NIH/NIDDK for Type 1 Diabetes Early Detection Test

SAN FRANCISCO, July 31, 2018 /PRNewswire/ -- Enable Biosciences Inc has been awarded a two-year National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) Small Business Innovation Research (SBIR) Phase II grant for $1.5 million to commercialize innovative technology by conducting research and development (R&D) work on low cost and multiplex tests for type 1 diabetes.

Type 1 diabetes (T1D) is an autoimmune disease that affects over a million Americans. Over one in 300 children under age 18 are affected. Up to 40% of new T1D cases coincide with potentially deadly diabetic ketoacidosis (DKA). DKA can be avoided by screening for autoantibody biomarkers, allowing doctors to intervene before major symptoms arise, but tests to detect these markers are generally considered too expensive for screening.

As a part of the award, Enable Biosciences is automating their Antibody Detection by Agglutination-PCR (ADAP) platform to reduce cost and increase throughput. With these improvements, Enable hopes to increase patient access to testing. Earlier detection of pre-diabetic individuals can improve overall care and link patients to clinical trials to potentially slow or halt progression to full type 1 diabetes.

"Developing new technologies to improve the lives of those with type 1 diabetes has been a part of Enable's DNA since its inception. We are pleased to receive NIH/NIDDK support to produce high-quality and accessible tests to allow physicians to intervene earlier and help patients with autoimmune diabetes lead healthier lives," said Cheng-Ting "Jason" Tsai, Ph.D., Chief Technology Officer at Enable Biosciences.

Early Disease Detection Technology Boosted by Phase II National Science Foundation Grant to Enable Biosciences

SAN FRANCISCO, July 17, 2018 /PRNewswire/ -- Enable Biosciences Inc was awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II grant for $750,000 to commercialize ultrasensitive and multiplexable immunoassays for both research and clinical diagnostic use.

Over 70% of clinical decisions are informed by lab tests, many of which rely on detecting antibody biomarkers. "For hundreds of infectious and autoimmune diseases and cancer, early detection makes the greatest difference to achieve a good outcome. More sensitive and accurate antibody tests are urgently needed," explains Enable's CEO David Seftel, M.D.

The NSF is an independent federal agency with a budget of about $7.5 billion that supports fundamental research and education across all fields of science and engineering.
The NSF is an independent federal agency with a budget of about $7.5 billion that supports fundamental research and education across all fields of science and engineering.
Enable's Antibody Detection by Agglutination-PCR technology (ADAP) is 1,000-10,000 more sensitive at detecting antibodies than existing methods. "Our NSF Phase I grant demonstrated that ADAP could accurately detect dozens of difficult disease markers simultaneously. This Phase II award will help us take this technology from bench to bedside," said Peter Robinson, PhD, Enable's Chief Scientific Officer. Funding from the National Science Foundation will support automation of the testing technology, creation and validation of new tests, ensuring compliance with regulatory standards and developing good manufacturing processes.

"The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts," said Barry Johnson, Director of Division of Industrial Innovation and Partnerships at NSF.

"We are thrilled to receive this ongoing support from the National Science Foundation," stated Cheng-ting Jason Tsai, PhD, Enable's Chief Technology Officer.

About Enable Biosciences: Enable is a diagnostics company based in San Francisco, CA commercializing licensed technology from UC Berkeley and Stanford University. (www.enablebiosciences.com.) Press inquiries: press@enablebiosciences.com